Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.69 |
| ▸ | MMP2 | P08253 | 9/20 | 0.62 |
| ▸ | MMP8 | P22894 | 8/20 | 0.62 |
| ▸ | MMP9 | P14780 | 7/20 | 0.62 |
| ▸ | ECE1 | P42892 | 3/20 | 0.60 |
| ▸ | MMP1 | P03956 | 6/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.54 |
| ▸ | ADAM12 | O43184 | 1/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | MMP15 | P51511 | 1/20 | 0.54 |
| ▸ | MMP16 | P51512 | 1/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.54 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.54 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193888 | 1.00 | TACR1 (0.69) | TACR1MMP2MMP8MMP9ECE1 | |
| SCHEMBL2680253 | 0.90 | MMP2 (0.72) | TACR1MMP2MMP8MMP9ECE1 | |
| SCHEMBL6431194 | 0.86 | ECE1 (0.79) | MMP2MMP8MMP9ECE1MMP1 | |
| SCHEMBL8200364 | 0.85 | TACR1 (0.86) | TACR1MMP8MMP9CCKBRMMP14 | |
| SCHEMBL8200367 | 0.85 | TACR1 (0.86) | TACR1MMP8MMP9CCKBRMMP14 | |
| SCHEMBL6439250 | 0.84 | MMP2 (0.80) | MMP2MMP8MMP9ECE1MMP1 | |
| SCHEMBL6577614 | 0.84 | MMP2 (0.80) | MMP2MMP8MMP9ECE1MMP1 | |
| SCHEMBL7765890 | 0.84 | MMP2 (0.80) | MMP2MMP8MMP9ECE1MMP1 | |
| SCHEMBL6438804 | 0.82 | MMP1 (0.67) | MMP2MMP8MMP9ECE1MMP1 | |
| SCHEMBL6575670 | 0.79 | MMP1 (0.84) | MMP2MMP8MMP9ECE1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | TACR1 2287/4885MMP2 19/4885MMP8 29/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | TACR1 2287/4885MMP2 19/4885MMP8 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.